Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02069392 · ClinicalTrials.gov registry record · NA
Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia
A NA study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT02069392 is a NA study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 31 participants.
The verdict
NCT02069392, a NA study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
Schizophrenia is marked by problems in attention, memory and problem solving. These deficits predict long-term functional outcome such as the ability to live independently and maintain employment, but they are not ameliorated by currently available medications. Cognitive training improves these functions to some degree, but this approach is time- and resource-intensive. The current project aims at enhancing and accelerating the benefits that people with schizophrenia derive from cognitive training by administering nicotine during some of the training sessions. This would provide the proof of principle for a type of treatment intervention to improve cognitive symptoms of schizophrenia. The current project aims at determining whether the intermittent presence of nicotine during cognitive training exercises in people with schizophrenia will shorten the training period necessary to induce significant and clinically relevant improvement and enhance the improvement seen after a training period of specified length. Hypothesis 1a: Nicotine administration during training will increase the size of all measured effects of the training intervention, and will accelerate the time course of performance enhancement on the MCCB and training exercise progression parameters. Hypothesis 1b: The larger training effects in the Nicotine Group will persist beyond the end of the intervention. Hypothesis 2a: Within-session progress on the training exercises will be larger in the presence of nicotine than in the presence of placebo. Hypothesis 2b: These acute nicotine-induced performance elevations will persist beyond the presence of nicotine through subsequent non-drug training sessions, giving evidence of an acute facilitation of learning processes.
Interventions
- BEHAVIORAL Cognitive remediation training
- DRUG Nicotine polacrilex lozenge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02069392
The ClinicalTrials.gov registry entry for NCT02069392 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cognitive remediation training is the first listed.
NCT02069392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02069392 about?
NCT02069392 is a clinical study titled "Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia". Schizophrenia is marked by problems in attention, memory and problem solving. These deficits predict long-term functional outcome such as the ability to live independently and maintain employment, but they are not ameliorated by currently available medications. Cognitive training improves these func...
What is the current status of trial NCT02069392?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2015-01. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02069392?
The interventions under investigation include: Cognitive remediation training (BEHAVIORAL), Nicotine polacrilex lozenge (DRUG).
Who is sponsoring clinical trial NCT02069392?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.